Fitness6 months ago
Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001With Growing Body of Clinical Evidence, ALX-001 is Ready to Commence Phase 2 Studies | BioSpace
NEW HAVEN, Conn., June 11, 2024 (GLOBE NEWSWIRE) — Allyx Therapeutics, a clinical-stage biotechnology company working to deliver a novel approach to preserve and protect synapses...
